医学专题—卫小春-骨质疏松诊疗.ppt

《医学专题—卫小春-骨质疏松诊疗.ppt》由会员分享，可在线阅读，更多相关《医学专题—卫小春-骨质疏松诊疗.ppt（43页珍藏版）》请在淘文阁 - 分享文档赚钱的网站上搜索。

1、起起 草草 过过 程程n n编写调查问卷，广泛征求意见编写调查问卷，广泛征求意见n n专家负责，分部撰写（脊柱骨折、髋部骨折、专家负责，分部撰写（脊柱骨折、髋部骨折、肱骨近端骨折、桡尺骨远端骨折、药物治疗）肱骨近端骨折、桡尺骨远端骨折、药物治疗）n n邱贵兴教授任组长，专家组集体讨论邱贵兴教授任组长，专家组集体讨论(toln)(toln)(toln)(toln)（关（关节、脊柱、创伤、内分泌、老年病等专家）节、脊柱、创伤、内分泌、老年病等专家）n n衷心感谢各位专家的辛勤劳动衷心感谢各位专家的辛勤劳动第一页，共四十三页。一一、概述概述(i sh)i sh)1.1.特点：属于脆性骨折特点：属于脆

2、性骨折特点：属于脆性骨折特点：属于脆性骨折 好发于老年人好发于老年人好发于老年人好发于老年人2.2.好发部位：脊柱、髋部、肱骨近端、桡尺骨远端好发部位：脊柱、髋部、肱骨近端、桡尺骨远端好发部位：脊柱、髋部、肱骨近端、桡尺骨远端好发部位：脊柱、髋部、肱骨近端、桡尺骨远端3.3.面临问题：内固定松动面临问题：内固定松动面临问题：内固定松动面临问题：内固定松动 再次骨折再次骨折再次骨折再次骨折 致残率及致残率及致残率及致残率及 致死率高致死率高致死率高致死率高4.4.治疗措施：骨折和骨质疏松治疗措施：骨折和骨质疏松治疗措施：骨折和骨质疏松治疗措施：骨折和骨质疏松(sh sn(sh sn)同时治疗同时

3、治疗同时治疗同时治疗第二页，共四十三页。二二、临床表现临床表现一般表现：出现压痛、疼痛或原有疼痛加重一般表现：出现压痛、疼痛或原有疼痛加重一般表现：出现压痛、疼痛或原有疼痛加重一般表现：出现压痛、疼痛或原有疼痛加重特有表现：出现畸形、骨擦感、反常活动、功能障碍特有表现：出现畸形、骨擦感、反常活动、功能障碍特有表现：出现畸形、骨擦感、反常活动、功能障碍特有表现：出现畸形、骨擦感、反常活动、功能障碍脊柱脊柱脊柱脊柱(j(j zh)zh)变形：身高变矮或驼背畸形变形：身高变矮或驼背畸形变形：身高变矮或驼背畸形变形：身高变矮或驼背畸形第三页，共四十三页。三三、诊断诊断(zhndun)(zhndun)与

4、鉴别诊断与鉴别诊断(zhndun)(zhndun)1.1.性别：女性多见，也可见于男性性别：女性多见，也可见于男性性别：女性多见，也可见于男性性别：女性多见，也可见于男性 2.2.年龄年龄年龄年龄(ninlng)(ninlng)：多见于：多见于：多见于：多见于6060岁以上老年人岁以上老年人岁以上老年人岁以上老年人 3.3.外伤史：仅为轻微外伤或无明显外伤史外伤史：仅为轻微外伤或无明显外伤史外伤史：仅为轻微外伤或无明显外伤史外伤史：仅为轻微外伤或无明显外伤史4.4.临床表现：疼痛、畸形、功能障碍临床表现：疼痛、畸形、功能障碍临床表现：疼痛、畸形、功能障碍临床表现：疼痛、畸形、功能障碍第四页，共

5、四十三页。三三、诊断诊断(zhndun)(zhndun)与鉴别诊断与鉴别诊断(zhndun)(zhndun)5.5.影像学检查影像学检查影像学检查影像学检查 ：一般要求拍摄正、侧位：一般要求拍摄正、侧位：一般要求拍摄正、侧位：一般要求拍摄正、侧位X X片合理应用片合理应用片合理应用片合理应用CTCT、MRIMRI、CTCT三维成像技术三维成像技术三维成像技术三维成像技术 6.6.骨密度检查骨密度检查骨密度检查骨密度检查 ：双能：双能：双能：双能X X线吸收法线吸收法线吸收法线吸收法(DXA)(DXA)7.7.实验室检查：血、尿常规，肝肾实验室检查：血、尿常规，肝肾实验室检查：血、尿常规，肝肾实

6、验室检查：血、尿常规，肝肾(n shn)n shn)功能，血糖、钙、功能，血糖、钙、功能，血糖、钙、功能，血糖、钙、磷、碱性磷酸酶、磷、碱性磷酸酶、磷、碱性磷酸酶、磷、碱性磷酸酶、25(OH)D25(OH)D和甲状旁腺激素等和甲状旁腺激素等和甲状旁腺激素等和甲状旁腺激素等第五页，共四十三页。三、三、诊断诊断(zhndun)(zhndun)与鉴别诊断与鉴别诊断(zhndun)(zhndun)8.8.8.8.鉴别诊断：骨肿瘤、继发性骨质疏松症和骨病导致的骨鉴别诊断：骨肿瘤、继发性骨质疏松症和骨病导致的骨鉴别诊断：骨肿瘤、继发性骨质疏松症和骨病导致的骨鉴别诊断：骨肿瘤、继发性骨质疏松症和骨病导致的骨

7、折折折折9.9.9.9.危险因素：危险因素：危险因素：危险因素：(1)(1)(1)(1)主要危险因素：低骨密度、脆性骨折史、高龄主要危险因素：低骨密度、脆性骨折史、高龄主要危险因素：低骨密度、脆性骨折史、高龄主要危险因素：低骨密度、脆性骨折史、高龄65656565岁、岁、岁、岁、骨折家族病史骨折家族病史骨折家族病史骨折家族病史(bn sh)(bn sh)(bn sh)(bn sh)(2)(2)(2)(2)次要危险因素：跌倒、抽烟、酗酒；性腺机能减退、次要危险因素：跌倒、抽烟、酗酒；性腺机能减退、次要危险因素：跌倒、抽烟、酗酒；性腺机能减退、次要危险因素：跌倒、抽烟、酗酒；性腺机能减退、早期绝经

8、（早期绝经（早期绝经（早期绝经（45454520202020，同时，同时，同时，同时-2.5SDT-1.0SD2.5SDT-1.0SD2.5SDT-1.0SD2.5SDT50505050岁男性岁男性岁男性岁男性2.T-2.5SD2.T-2.5SD2.T-2.5SD2.T-2.5SD者者者者3.3.3.3.骨质疏松性骨折（髋部、脊柱）患者骨质疏松性骨折（髋部、脊柱）患者骨质疏松性骨折（髋部、脊柱）患者骨质疏松性骨折（髋部、脊柱）患者4.4.4.4.继发性骨质疏松症伴有骨折高危因素者继发性骨质疏松症伴有骨折高危因素者继发性骨质疏松症伴有骨折高危因素者继发性骨质疏松症伴有骨折高危因素者5.5.5.5

9、.有骨折史伴有低骨密度（有骨折史伴有低骨密度（有骨折史伴有低骨密度（有骨折史伴有低骨密度（-2.5SDT-1.0SD-2.5SDT-1.0SD-2.5SDT-1.0SD-2.5SDT651.651.651.65岁女性、岁女性、岁女性、岁女性、70707070岁男性，需进行骨密度检测岁男性，需进行骨密度检测岁男性，需进行骨密度检测岁男性，需进行骨密度检测2.2.2.2.绝经后妇女、绝经后妇女、绝经后妇女、绝经后妇女、5050505070707070岁男性，依临床危险岁男性，依临床危险岁男性，依临床危险岁男性，依临床危险(wixin)(wixin)(wixin)(wixin)因素因素因素因素程度每

10、两年进行一次骨密度检测程度每两年进行一次骨密度检测程度每两年进行一次骨密度检测程度每两年进行一次骨密度检测3.3.3.3.经期过渡期伴有危险因素者（如低体重、脆性骨折史、经期过渡期伴有危险因素者（如低体重、脆性骨折史、经期过渡期伴有危险因素者（如低体重、脆性骨折史、经期过渡期伴有危险因素者（如低体重、脆性骨折史、服用某些药物史）服用某些药物史）服用某些药物史）服用某些药物史）4.504.504.504.50岁成人且有骨折史者岁成人且有骨折史者岁成人且有骨折史者岁成人且有骨折史者第三十六页，共四十三页。六六.预预 防防（二）哪些人员需要进行风险评估（二）哪些人员需要进行风险评估（二）哪些人员需要

11、进行风险评估（二）哪些人员需要进行风险评估5.5.5.5.继发性骨质疏松症患者（如类风湿性关节炎、服用激继发性骨质疏松症患者（如类风湿性关节炎、服用激继发性骨质疏松症患者（如类风湿性关节炎、服用激继发性骨质疏松症患者（如类风湿性关节炎、服用激素史、低骨量）素史、低骨量）素史、低骨量）素史、低骨量）6.6.6.6.接受骨质疏松症治疗或正在接受骨质疏松症治疗或正在接受骨质疏松症治疗或正在接受骨质疏松症治疗或正在(zhngzi)(zhngzi)(zhngzi)(zhngzi)观察疗效者观察疗效者观察疗效者观察疗效者7.7.7.7.显示骨丢失而需接受治疗者显示骨丢失而需接受治疗者显示骨丢失而需接受治疗

12、者显示骨丢失而需接受治疗者8.8.8.8.经期后妇女如停止雌激素治疗者经期后妇女如停止雌激素治疗者经期后妇女如停止雌激素治疗者经期后妇女如停止雌激素治疗者第三十七页，共四十三页。六六.预预 防防（三）患者的自我管理（三）患者的自我管理（三）患者的自我管理（三）患者的自我管理1.1.1.1.坚持坚持坚持坚持(jinch)(jinch)(jinch)(jinch)预防预防预防预防2.2.2.2.戒烟限酒戒烟限酒戒烟限酒戒烟限酒3.3.3.3.减肥减肥减肥减肥4.4.4.4.增加肌力运动增加肌力运动增加肌力运动增加肌力运动5.5.5.5.预防跌倒预防跌倒预防跌倒预防跌倒第三十八页，共四十三页。参参

13、考考 文文 献献Cummings SRCummings SRCummings SRCummings SR，Kelsey JL.Epidemiology of osteoporosis and Kelsey JL.Epidemiology of osteoporosis and Kelsey JL.Epidemiology of osteoporosis and Kelsey JL.Epidemiology of osteoporosis and osteoporotic fractures.Epidemiol Rev,1985,7:178-208osteoporotic fractures.E

14、pidemiol Rev,1985,7:178-208osteoporotic fractures.Epidemiol Rev,1985,7:178-208osteoporotic fractures.Epidemiol Rev,1985,7:178-208Camero S.Care of older people.Falls in late life and their Camero S.Care of older people.Falls in late life and their Camero S.Care of older people.Falls in late life and

15、their Camero S.Care of older people.Falls in late life and their consequences implementing effective services.Br Med consequences implementing effective services.Br Med consequences implementing effective services.Br Med consequences implementing effective services.Br Med J,2001,322(7290):855-857.J,

16、2001,322(7290):855-857.J,2001,322(7290):855-857.J,2001,322(7290):855-857.Hoesel LMHoesel LMHoesel LMHoesel LM,Pausch MPausch MPausch MPausch M,Schnettler RSchnettler RSchnettler RSchnettler R,Heiss CHeiss CHeiss CHeiss C.The impact of.The impact of.The impact of.The impact of osteoporosis on the cla

17、ssification of hip and wrist fractures.osteoporosis on the classification of hip and wrist fractures.osteoporosis on the classification of hip and wrist fractures.osteoporosis on the classification of hip and wrist fractures.Med Sci Monit.2008,14(3):HY1-8.Med Sci Monit.2008,14(3):HY1-8.Med Sci Monit

18、.2008,14(3):HY1-8.Med Sci Monit.2008,14(3):HY1-8.Tuck SPTuck SPTuck SPTuck SP,Datta HKDatta HKDatta HKDatta HK.Osteoporosis in the aging male:treatment.Osteoporosis in the aging male:treatment.Osteoporosis in the aging male:treatment.Osteoporosis in the aging male:treatment options.Clin Interv Aging

19、.2007,2(4):521-36options.Clin Interv Aging.2007,2(4):521-36options.Clin Interv Aging.2007,2(4):521-36options.Clin Interv Aging.2007,2(4):521-36第三十九页，共四十三页。参参 考考 文文 献献Tuck SPTuck SPTuck SPTuck SP,Datta HKDatta HKDatta HKDatta HK.Osteoporosis in the aging male:treatment options.Osteoporosis in the agi

20、ng male:treatment options.Osteoporosis in the aging male:treatment options.Osteoporosis in the aging male:treatment options.Clin Interv Aging.2007,2(4):521-36Lyritis GP,Paspati,et al.Pain Clin Interv Aging.2007,2(4):521-36Lyritis GP,Paspati,et al.Pain Clin Interv Aging.2007,2(4):521-36Lyritis GP,Pas

21、pati,et al.Pain Clin Interv Aging.2007,2(4):521-36Lyritis GP,Paspati,et al.Pain relief from nasal salmon calcitonin in osteoporotic vertebral crush relief from nasal salmon calcitonin in osteoporotic vertebral crush relief from nasal salmon calcitonin in osteoporotic vertebral crush relief from nasa

22、l salmon calcitonin in osteoporotic vertebral crush fractures.A double blind,placebo-controlled clinical study.Acta fractures.A double blind,placebo-controlled clinical study.Acta fractures.A double blind,placebo-controlled clinical study.Acta fractures.A double blind,placebo-controlled clinical stu

23、dy.Acta Orthop Scand Suppl.1997 Oct;275:112-4.Orthop Scand Suppl.1997 Oct;275:112-4.Orthop Scand Suppl.1997 Oct;275:112-4.Orthop Scand Suppl.1997 Oct;275:112-4.Charles H Chesnut,et al.Effects of salmon calcitonin on Charles H Chesnut,et al.Effects of salmon calcitonin on Charles H Chesnut,et al.Effe

24、cts of salmon calcitonin on Charles H Chesnut,et al.Effects of salmon calcitonin on trabecular microarchitecture as determined by magnetic trabecular microarchitecture as determined by magnetic trabecular microarchitecture as determined by magnetic trabecular microarchitecture as determined by magne

25、tic resonance imaging:results from the quest study.J Bone resonance imaging:results from the quest study.J Bone resonance imaging:results from the quest study.J Bone resonance imaging:results from the quest study.J Bone Miner Res 2005;20:1548-1561Miner Res 2005;20:1548-1561Miner Res 2005;20:1548-156

26、1Miner Res 2005;20:1548-1561Chesnut CH 3rd,Silverman S,Andriano K,et al.A randomized trial of Chesnut CH 3rd,Silverman S,Andriano K,et al.A randomized trial of Chesnut CH 3rd,Silverman S,Andriano K,et al.A randomized trial of Chesnut CH 3rd,Silverman S,Andriano K,et al.A randomized trial of nasal sp

27、ray salmon calcitonin in postmenopausal women with nasal spray salmon calcitonin in postmenopausal women with nasal spray salmon calcitonin in postmenopausal women with nasal spray salmon calcitonin in postmenopausal women with established osteoporosis:the prevent recurrence of osteoporotic establis

28、hed osteoporosis:the prevent recurrence of osteoporotic established osteoporosis:the prevent recurrence of osteoporotic established osteoporosis:the prevent recurrence of osteoporotic fractures study.Am J Med,2000,109:267-276.fractures study.Am J Med,2000,109:267-276.fractures study.Am J Med,2000,10

29、9:267-276.fractures study.Am J Med,2000,109:267-276.第四十页，共四十三页。参参 考考 文文 献献Scott A.et al,Whats New in Orthopaedic Research,J Bone Scott A.et al,Whats New in Orthopaedic Research,J Bone Scott A.et al,Whats New in Orthopaedic Research,J Bone Scott A.et al,Whats New in Orthopaedic Research,J Bone Joint

30、Surg Am.,2004;86:2085-2095.Joint Surg Am.,2004;86:2085-2095.Joint Surg Am.,2004;86:2085-2095.Joint Surg Am.,2004;86:2085-2095.Scott A.Rodeo,Suzanne A.Maher and Chisa Hidaka,Whats Scott A.Rodeo,Suzanne A.Maher and Chisa Hidaka,Whats Scott A.Rodeo,Suzanne A.Maher and Chisa Hidaka,Whats Scott A.Rodeo,S

31、uzanne A.Maher and Chisa Hidaka,Whats New in Orthopaedic Research,J Bone Joint Surg Am.,2004;New in Orthopaedic Research,J Bone Joint Surg Am.,2004;New in Orthopaedic Research,J Bone Joint Surg Am.,2004;New in Orthopaedic Research,J Bone Joint Surg Am.,2004;86:2085-2095.86:2085-2095.86:2085-2095.86:

32、2085-2095.中华医学会骨质疏松和骨矿盐中华医学会骨质疏松和骨矿盐中华医学会骨质疏松和骨矿盐中华医学会骨质疏松和骨矿盐(kun yn)(kun yn)(kun yn)(kun yn)疾病分会疾病分会疾病分会疾病分会原发性骨质疏松症诊原发性骨质疏松症诊原发性骨质疏松症诊原发性骨质疏松症诊治指南治指南治指南治指南 Brown JP,et al.2002 clinical practice guidelines for the Brown JP,et al.2002 clinical practice guidelines for the Brown JP,et al.2002 clinica

33、l practice guidelines for the Brown JP,et al.2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada.CMAJ.diagnosis and management of osteoporosis in Canada.CMAJ.diagnosis and management of osteoporosis in Canada.CMAJ.diagnosis and management of osteoporosis in C

34、anada.CMAJ.2002;167:sl-s342002;167:sl-s342002;167:sl-s342002;167:sl-s34第四十一页，共四十三页。参参 考考 文文 献献Meunier PJ,et al.The effects of Strontium Ranelate on the risk of Meunier PJ,et al.The effects of Strontium Ranelate on the risk of Meunier PJ,et al.The effects of Strontium Ranelate on the risk of Meunier

35、PJ,et al.The effects of Strontium Ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis(vertebral fracture in women with postmenopausal osteoporosis(vertebral fracture in women with postmenopausal osteoporosis(vertebral fracture in women with postmenopausal osteoporosi

36、s(SOTI),N Engl J Med 2004;350:459-68SOTI),N Engl J Med 2004;350:459-68SOTI),N Engl J Med 2004;350:459-68SOTI),N Engl J Med 2004;350:459-68J.-Y.Reginster,E.Seeman,et al.Strontium Ranelate Reduces J.-Y.Reginster,E.Seeman,et al.Strontium Ranelate Reduces J.-Y.Reginster,E.Seeman,et al.Strontium Ranelate

37、 Reduces J.-Y.Reginster,E.Seeman,et al.Strontium Ranelate Reduces the Risk of Nonvertebral Fractures in Postmenopausal Women the Risk of Nonvertebral Fractures in Postmenopausal Women the Risk of Nonvertebral Fractures in Postmenopausal Women the Risk of Nonvertebral Fractures in Postmenopausal Wome

38、n with Osteoporosis:Treatment of Peripheral Osteoporosis with Osteoporosis:Treatment of Peripheral Osteoporosis with Osteoporosis:Treatment of Peripheral Osteoporosis with Osteoporosis:Treatment of Peripheral Osteoporosis(TROPOS)Study.Journal of Clinical Endocrinology and(TROPOS)Study.Journal of Cli

39、nical Endocrinology and(TROPOS)Study.Journal of Clinical Endocrinology and(TROPOS)Study.Journal of Clinical Endocrinology and Metabolism 2005;90:2816-2822 Metabolism 2005;90:2816-2822 Metabolism 2005;90:2816-2822 Metabolism 2005;90:2816-2822 Huusko TM,et al.Randomized double blind clinically control

40、led Huusko TM,et al.Randomized double blind clinically controlled Huusko TM,et al.Randomized double blind clinically controlled Huusko TM,et al.Randomized double blind clinically controlled trial of intranasal calcitonin treatment in patients with trial of intranasal calcitonin treatment in patients

41、 with trial of intranasal calcitonin treatment in patients with trial of intranasal calcitonin treatment in patients with hip fracture.Calcif Tissre Int 2002,71:478-484hip fracture.Calcif Tissre Int 2002,71:478-484hip fracture.Calcif Tissre Int 2002,71:478-484hip fracture.Calcif Tissre Int 2002,71:478-484第四十二页，共四十三页。内容(nirng)总结起 草 过 程。近年发现他汀类制剂及雷奈酸锶在抗骨吸收的同时也有促进成骨的作用。6必须注意用药前后血钙或尿钙的变化，原则上应用(yngyng)活性VitD3的同时要有意识地提高饮食中的钙含量。1包括股骨颈骨折和股骨转子间骨折。2累及关节面的桡骨远端粉碎性骨折、不稳定的桡骨远端骨折倾向于手术治疗。（4）腕关节镜技术目前已应用(yngyng)到关节面骨折的复位及骨折后关节内紊乱征的治疗第四十三页，共四十三页。